Stocks Health care GMAB
NASDAQ · Health careGenmab A/S (GMAB)
Genmab A/S reported revenue of $3.7B in fiscal 2025, up 19.2% from a year earlier. Net income was $963M, a net margin of 25.9%. Operating cash flow minus capital spending left $1.1B of free cash flow in fiscal 2025. At December 31, 2025 it held $1.7B in cash against $5.3B of debt.
Watch GMAB in 60 secondsWhat Genmab A/S does
Genmab A/S is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GMAB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3.7B | $963M | $15.37 | $1.1B |
| 2025 | $3.1B | $1.1B | $17.53 | $1.1B |
| 2023 | $2.4B | $631M | $9.58 | $1B |
Full financial statements: income, balance sheet and cash flow
Where GMAB ranks in Health care
Latest SEC filings
What Genmab A/S has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 24, 2026
- September 9, 2026
- September 9, 2026
- September 8, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 11, 2026
- August 6, 2026
- July 15, 2026
- June 29, 2026
Insider trades
What the people running Genmab A/S did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns GMAB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Orbis Investment Management Ltd13G, passive with 1 related filers | 5.3% | August 14, 2026 |
Largest institutional holders
Insiders
Questions about GMAB
What does Genmab A/S do?
Genmab A/S is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GMAB.
Is Genmab A/S profitable?
Yes. In fiscal 2025 it reported net income of $963M on revenue of $3.7B, a net margin of 25.9%.
How much revenue does Genmab A/S make?
In fiscal 2025 Genmab A/S reported revenue of $3.7B. That is 19.2% more than a year earlier.
When did Genmab A/S last report?
Its newest filing of any kind is the foreign issuer update from September 24, 2026.
Similar companies
Compare GMAB with
Follow GMAB
Get an email when Genmab A/S files with the SEC: results, executive changes, material agreements and annual reports.
Follow GMAB: get an email when it filesWhere the numbers come from
Financial figures are the values Genmab A/S tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.